Adverse events following COVID-19 vaccination in Kwara State, North-central Nigeria.
Journal
PLOS global public health
ISSN: 2767-3375
Titre abrégé: PLOS Glob Public Health
Pays: United States
ID NLM: 9918283779606676
Informations de publication
Date de publication:
2022
2022
Historique:
received:
24
03
2022
accepted:
05
07
2022
entrez:
24
3
2023
pubmed:
25
3
2023
medline:
25
3
2023
Statut:
epublish
Résumé
Safe and effective vaccination remains the mainstay of control of COVID-19 because there is still no universally recommended treatment. This strategy is however being threatened by vaccine hesitancy and resistance due to fear of adverse events and safety concerns. It is, therefore, necessary to study post-vaccination adverse events (AE) in various populations and geographical areas. The objective of this study was to analyze the adverse events following COVID-19 vaccination in five major immunization centers of Kwara State Nigeria. A retrospective descriptive study of the adverse events following AstraZeneca COVID-19 vaccination that were reported from five immunization centers of Kwara State, North-central Nigeria from March to July 2021 was carried out. Statistical Package for Social Science version 26 was used for analysis. Adverse event classification and severity were compared based on age, gender, and time to onset of adverse event and vaccine dose type using the Chi-square test. The incidence of COVID-19 vaccine AE was 1.6%. There was female predominance (51.6%) and a mean age of 41.6±13.7 years. Most of the AE (95.8%) were systemic and mild (81.1%) without a requirement for any therapeutic intervention. Fatal outcome was not reported in any of the AE and the time to outcome of AE was 2 days in most cases (45.3%). No significant association was found between the variables studied and the adverse event type and severity. The low incidence and mild nature of adverse events reported in this study will add to the body of knowledge regarding vaccine adverse events and may eventually impact vaccine uptake.
Identifiants
pubmed: 36962774
doi: 10.1371/journal.pgph.0000835
pii: PGPH-D-22-00480
pmc: PMC10021916
doi:
Types de publication
Journal Article
Langues
eng
Pagination
e0000835Informations de copyright
Copyright: © 2022 Odeigah et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Déclaration de conflit d'intérêts
The authors have declared that no competing interests exist.
Références
PLoS One. 2021 Dec 21;16(12):e0260638
pubmed: 34932553
Lancet. 2021 Jan 9;397(10269):99-111
pubmed: 33306989
J Korean Med Sci. 2021 Apr 12;36(14):e107
pubmed: 33847085
Turk J Pharm Sci. 2022 Dec 21;19(6):686-693
pubmed: 36544388
BMC Health Serv Res. 2019 Dec 3;19(1):926
pubmed: 31796034
BMC Pharmacol Toxicol. 2021 Oct 12;22(1):58
pubmed: 34641944
Infect Drug Resist. 2021 Oct 02;14:4077-4083
pubmed: 34629882
Diabetes Metab Syndr. 2020 Sep - Oct;14(5):779-788
pubmed: 32526627
Acta Biomed. 2020 Mar 19;91(1):157-160
pubmed: 32191675
Lancet. 2021 Dec 19;396(10267):1979-1993
pubmed: 33220855
J Korean Med Sci. 2021 May 03;36(17):e114
pubmed: 33942578
J Mark Access Health Policy. 2015 Aug 12;3:
pubmed: 27123187
J Korean Med Sci. 2021 May 03;36(17):e115
pubmed: 33942579
Int J Gen Med. 2021 Jul 27;14:3909-3927
pubmed: 34349544
PLoS One. 2017 Mar 1;12(3):e0172310
pubmed: 28249006